Vycor Medical, Inc.
VYCO
$0.07
$0.00-1.71%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -8.41% | 31.44% | 22.18% | 29.50% | 47.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.41% | 31.44% | 22.18% | 29.50% | 47.70% |
| Cost of Revenue | 41.00% | 68.21% | 130.40% | 110.27% | 37.62% |
| Gross Profit | -15.60% | 27.62% | 11.91% | 19.50% | 49.29% |
| SG&A Expenses | 0.14% | 10.08% | 2.13% | 19.04% | 13.64% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 3.47% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.01% | 13.08% | 14.12% | 29.64% | 17.08% |
| Operating Income | -289.12% | 191.45% | 215.43% | -34.74% | 130.11% |
| Income Before Tax | -831.34% | 108.36% | 357.00% | -26.23% | 92.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -831.34% | 108.36% | 357.00% | -26.23% | 92.56% |
| Earnings from Discontinued Operations | -200.00% | -- | -- | 100.00% | 96.77% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -835.82% | 108.19% | 339.00% | -26.14% | 92.80% |
| EBIT | -289.12% | 191.45% | 215.43% | -34.74% | 130.11% |
| EBITDA | -156.35% | 347.42% | 107.52% | -45.90% | 173.88% |
| EPS Basic | -850.00% | 29.85% | 333.33% | -1.69% | 93.10% |
| Normalized Basic EPS | -1,100.00% | 109.09% | 350.00% | -16.67% | 94.12% |
| EPS Diluted | -850.00% | 29.85% | 300.00% | -1.69% | 93.10% |
| Normalized Diluted EPS | -1,100.00% | 109.09% | 300.00% | -16.67% | 94.12% |
| Average Basic Shares Outstanding | -0.01% | 1.43% | 2.28% | 2.28% | 2.29% |
| Average Diluted Shares Outstanding | -0.01% | 1.43% | 18.51% | 2.28% | 2.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |